Presence or absence of study identifier in the published article | ||
---|---|---|
Yes (n = 71) | No (n = 18) | |
Study phase, n (%) | ||
Phase 1 | 17 (24) | 12 (67) |
Phase 2 | 38 (54) | 6 (33) |
Phase 3 | 16 (23) | 0 |
Drug type, n (%) | ||
Immune checkpoint inhibitors | 18 (25) | 1 (6) |
Other anticancer drugs | 53 (75) | 17 (94) |
Sample size, median (interquartile range) | 102 (53–345) | 42 (37–56) |
Multi-country study, n (%) | 46 (65) | 5 (28) |
Author affiliation with industry, n (%) | 71 (100) | 16 (89) |
Statistically significant outcomeª, n (%) | 17 (24) | 0 |
Reporting of adverse events, n (%) | 71 (100) | 18 (100) |
Selective outcome reporting, n (%) | 8 (11) | 7 (39) |